Cargando…

On tuberculosis and COVID-19 co-infection

COVID-19 may boost tuberculosis given infection and mortality, further studies are needed https://bit.ly/2Z2r5XO

Detalles Bibliográficos
Autores principales:	Tadolini, Marina, García-García, José-María, Blanc, François-Xavier, Borisov, Sergey, Goletti, Delia, Motta, Ilaria, Codecasa, Luigi Ruffo, Tiberi, Simon, Sotgiu, Giovanni, Migliori, Giovanni Battista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315815/ https://www.ncbi.nlm.nih.gov/pubmed/32586888 http://dx.doi.org/10.1183/13993003.02328-2020

Ejemplares similares

Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
por: Tadolini, Marina, et al.
Publicado: (2020)

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

COVID-19 Hampered Diagnosis of TB Infection in France, Italy, Spain and the United Kingdom
por: García-García, José-María, et al.
Publicado: (2022)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Global reporting on tuberculosis preventive treatment among contacts
por: Falzon, Dennis, et al.
Publicado: (2022)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Universal use of face masks for success against COVID-19: evidence and implications for prevention policies
por: Esposito, Susanna, et al.
Publicado: (2020)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study
por: Gupta, Rishi K., et al.
Publicado: (2021)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study
por: Aliberti, Stefano, et al.
Publicado: (2020)

Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study
por: Nalunjogi, Joanitah, et al.
Publicado: (2023)

Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors
por: Rinaldo, Rocco Francesco, et al.
Publicado: (2021)

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
por: Ndjeka, Norbert, et al.
Publicado: (2020)

Utility and safety of bronchoscopy during the SARS-CoV-2 outbreak in Italy: a retrospective, multicentre study
por: Mondoni, Michele, et al.
Publicado: (2020)

Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy
por: Magro, Paola, et al.
Publicado: (2020)

Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital
por: Stochino, Claudia, et al.
Publicado: (2020)

Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2022)

Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan
por: Lee, Meng-Rui, et al.
Publicado: (2017)

Tuberculosis prevention must integrate technological and basic care innovation
por: Mason, Paul H., et al.
Publicado: (2016)

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union
por: van der Werf, Marieke J., et al.
Publicado: (2017)

The potential impact of COVID-19-related disruption on tuberculosis burden
por: McQuaid, C. Finn, et al.
Publicado: (2020)

Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China
por: Chen, Hongguang, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe
por: Nikolayevskyy, Vladyslav, et al.
Publicado: (2021)

QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection
por: Saluzzo, Francesca, et al.
Publicado: (2022)

Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection
por: Frija-Masson, Justine, et al.
Publicado: (2020)

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
por: Blok, Nick, et al.
Publicado: (2016)

The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region
por: Chiang, Chen-Yuan, et al.
Publicado: (2020)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience
por: Sinkou, Heorhi, et al.
Publicado: (2017)

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis
por: Tornheim, Jeffrey A., et al.
Publicado: (2022)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis
por: Gupta, Nitesh, et al.
Publicado: (2020)

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
por: Masini, Tiziana, et al.
Publicado: (2022)

Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?
por: Giannini, Margherita, et al.
Publicado: (2020)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n3odm57vqk53rpf28efchstp42